DaVita Inc. $DVA Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 16.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,490 shares of the company’s stock after selling 6,107 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $4,051,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. National Pension Service acquired a new position in shares of DaVita during the third quarter valued at $1,305,000. Todd Asset Management LLC acquired a new stake in shares of DaVita in the 3rd quarter worth about $21,842,000. Intech Investment Management LLC lifted its position in DaVita by 122.4% in the 3rd quarter. Intech Investment Management LLC now owns 27,441 shares of the company’s stock valued at $3,646,000 after purchasing an additional 15,104 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in DaVita by 1,951.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 68,408 shares of the company’s stock valued at $9,089,000 after purchasing an additional 65,074 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in DaVita by 175.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,409 shares of the company’s stock valued at $2,446,000 after purchasing an additional 11,718 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DVA. Barclays increased their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. UBS Group lifted their price objective on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Finally, TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $155.80.

DaVita Trading Up 0.7%

Shares of NYSE DVA opened at $150.94 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $159.42. The firm has a 50-day moving average of $127.93 and a two-hundred day moving average of $126.58. The company has a market capitalization of $10.08 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.53 and a beta of 0.94.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the firm earned $2.24 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.